Adicet Bio 1 article

The cell-therapy profile of Adicet Bio combines allogeneic gamma delta CAR-T therapy with off-the-shelf cellular immunotherapy. A further distinguishing element is autoimmune disease cell therapy, which helps define how the therapeutic cells are sourced, modified or deployed. A final recognition cue is allogeneic CAR-T manufacturing, which remains a stable part of the scientific profile of Adicet Bio.

Clinical Trials & Evidence

September 19, 2026, 12:29 PM · 5 mins read

CAR-T clinical trial pipeline accelerates as over 180 companies advance next generation therapies

A surge of more than 180 companies is driving over 200 CAR-T therapies through the clinical pipeline, with new strategies aiming to overcome resistance and expand beyond cancer.